Skip to search boxSkip to navigationSkip to main content

2021 DORIS definition of remission in SLE: Final recommendations from an international task force

  • Ronald F. van Vollenhoven(corresponding author)
    ,
  • George Bertsias
    ,
  • Andrea Doria
    ,
  • David Isenberg
    ,
  • Eric Morand
    ,
  • Michelle A. Petri
*Corresponding author for this work
  • Amsterdam Rheumatology and Immunology Center
    ,
  • University Hospital of Heraklion
    ,
  • University of Padova
    ,
  • University College London
    ,
  • Monash Medical Centre
    ,
  • Johns Hopkins University School of Medicine
Research Output:
Contribution to journal
Review article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Review article
Peer-review

Original language

English

Article number

e000538

Journal (Volume, Issue Number)

Lupus Science and Medicine (Volume 8, Issue 1)

Publication milestones

  • Published - 24/11/2021

Publication status

Published - 24/11/2021

Publication IDs

  • Scopus: 85121234911

Abstract

Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. Methods Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. Results Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.

Funding Details

Funding The DORIS Initiative was supported by unrestricted educational grants from Glaxo SmithKline and UCB Pharma.
FundersFunding numbers
Eli Lilly and Company
-
Pfizer
-
GSK
-
Gilead Sciences
-
Actelion Pharmaceuticals
-
Boehringer Ingelheim
-
Janssen Pharmaceuticals
-
UCB
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Citations
242
Mentions
3
Captures
191
Social media
2